CaredioDavide

Happy to see this work now published in PLOS Pathogens. We identify TFAP2C as a functional interactor of hnRNPK and show how this axis regulates prion propagation via mTORC1 signaling. Great team effort—congrats to Stefano Sellitto and all co-authors!

I’m excited to share that my first-author paper has just been published in PLOS Pathogens! journals.plos.org/plospathogens/…

Excited to share two back-to-back studies with @jonykipnis @boskovic_p showing the promise of CAR T beyond cancer — in Alzheimer’s and stroke — inspired by the visionary work of Zelig Eshhar.

Excited to share our new work on immune aging! We explored whether the liver could serve as a temporary "factory" to produce immune factors that decline with aging, potentially helping to rejuvenate aged immunity. @mircoscopy.

We have now reached a new level of spatial omics: translatomics! nature.com/articles/s4159… Fascinating new tech in new paper "Scalable spatial single-cell transcriptomics and translatomics in 3D thick tissue blocks" from @naturemethods

Very elegant work from an amazing Italian scientist @SimonaParrinello! Axonal injury → Wallerian degeneration → neuroinflammation → glioma growth. And it’s targetable. #Glioma #Neuroinflammation #BrainCancer #Nature Congratulations to all the author of this beautiful work!

🧬 BREAKING: Our CRISPR-GPT paper is out TODAY in Nature Biomedical Engineering @natBME ! 🤯 We built an AI agent that turns ANYONE into a gene-editing expert in 1 DAY instead of months. An undergrad with ZERO experience achieved 90%+ editing efficiency on their FIRST attempt. 🧵 Here's how we're building expert AI agents for cutting-edge biotechnology: 🎯 The Problem: CRISPR is revolutionary but requires PhD-level expertise, it can take weeks to learn, adopt, and design, analyze a CRISPR experiment for R&D or making life-saving medicine. Even Pro scientists can make small mistakes (e.g. typos in guideRNA or cloning design) that cost months to find out, slowing us down. 💡 Our Solution: CRISPR-GPT - an AI co-pilot from @Stanford @Princeton @GoogleDeepMind that guides you through EVERY step via simple conversation 🔬 Real Results: -Novice researcher: ~90% editing on 1st go -Training time: Months → 1 day -100% success rate in our trials -Even experts save days/weeks on data analysis & troubleshooting 🤖 How it works: Our multi-agent system handles: CRISPR system and delivery method selection, guideRNA design, Protocol generation, Real-time troubleshooting, Data analysis, and beyond. All through natural language! No coding, no complex software. 📊 We benchmarked it extensively: -288 evaluation scenarios/cases -Outperformed GPT-4o on ALL gene editing tasks -Trained on 11 years of expert discussions -Covers knockout, base-editing, prime-editing & epigenetic editing 🌍 Why this matters: -Every lab can now use CRISPR with an AI system distilling expert knowledge and skills. -Every student can learn faster. -Every researcher can tackle bigger challenges without worrying about small mistakes. -Customized CRISPR design can be automated based on your need and the context of R&D workflow. -Agentic AI ensure safety, privacy, and responsibility -We're not just automating gene editing - we're using AI to power scientists to cure diseases. 🚀 Try it yourself! Beta access available at: genomics.stanford.edu Paper: nature.com/articles/s4155… Code: github.com/cong-lab/crisp… Benchmark (companion work, Genome-bench): github.com/mingyin0312/RL… Co-first and key authors: @YuanhaoQ @KaixuanHuang1 @MingYin_0312 PIs: @lecong @MengdiWang10 Key collaborators: @Rbaltman @denny_zhou The future of biology and science is conversational. The future is now. @natBME @NaturePortfolio #CRISPR #AI #GeneEditing #Biotech #Science #AISafety

In this study, we generated a Slco1c1-CreERmouse line (Slco1c1-KI-P2A-iCreERT2, briefly, Slco1c1-CreERKI). Our staining results validate its high specificity for labeling CNS endothelial cells, with rare expression in peripheral endothelial cells. nature.com/articles/s4146…

Our study on glioblastoma-associated immunoregulatory astrocytes is out in @Nature today by @CamiloFaustAkl! We identified GBM-derived IL-11 as a regulator of TRAIL+ astrocytes, which limit anti-tumor T cell responses via apoptosis. nature.com/articles/s4158…

Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity @Nature nature.com/articles/s4158…

ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses: …arneurodegeneration.biomedcentral.com/articles/10.11…

'A versatile mouse model to advance human #microglia transplantation research in #neurodegenerative diseases' Lutgarde Serneels @ASierksma @EmanuelaPasciu1 Ivana Geric...Bart De Strooper @CBD_VIB @KU_Leuven @UKDRI #AlzheimersDisease #xenotransplantation bit.ly/3DANTGt

Analysis of CSF GPNMB levels in 118 sporadic #Parkinsons cases (& 40 controls) finds higher levels than controls, correlating with age & the severity of motor & cognitive dysfunction journals.sagepub.com/doi/full/10.11…

Rust et al. examine the structure of the blood–brain barrier, highlighting changes with aging, neurodegeneration, and injury. They discuss how BBB disruption can accelerate disease progression, and review emerging drug delivery strategies. tinyurl.com/ykrwr7wn

biorxiv.org/content/10.110… I'm really pleased to share this preprint comprising the bulk of Lizzie Hill's work for PhD on the role of STX6 in prion and tau neurodegenerative diseases @MRC_Prion @lizziehill35 Short thread 1/n

The first clinical results in patients with a genetic form of frontotemporal dementia show that enhancing progranulin in the brain may halt disease progression nature.com/articles/s4158…

At the beginning of 2025 Daniel Kirschenbaum has started his work as Junior Research Group Leader at DKFZ. "I explore the dynamic changes and interactions of the immune system in cancer, blending curiosity-driven science with cutting-edge technology development." Welcome to DKFZ!

#SpatioTemporal #NeuroImmuneCrossTalk Loooong time to shape it but rewarding 😎 The second first-author publication from my PhD work. In prion disease, microglia respond to cell death by upregulating GPNMB which enhances phagocytosis and lysosomal function.

Our paper is out now in Neurobiology of Disease. Investigating the E631K mutation in the CSF1R gene we show that #microglia density and expansion is reduced but does not affect CNS #prion disease sciencedirect.com/science/articl…

@neilmabbott1 Congrats 👏🏻 ! Very interesting study